Vasopressin manufacturers & suppliers

Vasopressin

Form: Intravenous (IV) Injection

Strength: 20 units/mL

Reference Brands: Vasostrict(US); Empressin, Vasopressin Aguettant, Vasopressin Stragen(EU)

Category: Critical Care

Vasopressin is a potent vasoconstrictor used in the treatment of septic shock, cardiac arrest, and diabetes insipidus. It is primarily available as a 20 units/mL IV injection in single or multi-dose vials. Vasopressin enhances blood pressure by acting on V1 receptors and is often combined with other catecholamines in ICU settings. In the US, Vasostrict was the leading brand, now available in generic versions. The EU markets feature brands like Empressin and Vasopressin Aguettant. As a high-demand critical care drug, vasopressin is routinely procured by hospitals, emergency departments, and healthcare distributors through B2B pharmaceutical platforms and institutional tenders.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details
Insulin (Iv)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.